Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Memory Problems In Patients With Fibromyalgia Not Linked To Risk For Alzheimer's

Wednesday 4 March 2015

 

From Healio Rheumatology:

 

Healio
 

Memory problems in patients with FM not linked to risk for Alzheimer's

By Shirley Pulawski
February 27, 2015

Leavitt F, et al. J Clin Rheumatol. 2015;doi:10.1097/RHU.0000000000000213.

Patients with fibromyalgia and severe episodes of memory problems or cognitive dysfunction, known as “fibrofog,” were not at higher risk for the development of Alzheimer’s disease, which has a different profile of memory loss, according to new research.

Frank Leavitt, PhD and Robert S. Katz, MD, of Rush Medical College in Chicago, studied 149 female patients with fibromyalgia (FM) confirmed by the American College of Rheumatology criteria. Based on a pre-examination questionnaire, in which patients were asked to report the duration of their memory problems, patients were divided into two cohorts: one with 94 participants who reported short-term cognitive problems (≤12 months; mean: 7.3 months), and one with 55 patients who reported long-term cognitive problems (≥84 months; mean: 13.3 years).

Patients were administered 12 tests related to cognition and function, including the Stroop Color and Word test, Controlled Oral Word Test, Logical Memory and Paired Associates, Trail-Making Tests A and B, Paced Serial Arithmetic Test and Beck Depression Inventory. Patients were also assessed for intelligence, vocabulary and education level, which were similar between groups.

Cognitive data showed no significant differences in levels of episodic cognitive memory, defined as recent and delayed recall of logical paragraphs and paired associates learning, according to the researchers. Additionally, no significant differences were seen between groups on 10 of the 11 remaining cognitive areas measured. However, performance declines were observed on the Trails A test in the group with a longer duration of cognitive problems.

Measures of episodic memory and processing speed, considered to be markers of preclinical Alzheimer’s disease, were in the normal range in both groups, according to the researchers. Delayed recall was found to be the most sensitive measure for distinguishing older adults with early Alzheimer’s disease from memory loss due to normal aging. – by Shirley Pulawski

Disclosures: The authors report no relevant financial disclosures.

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page